A recognizable medication name is not enough to establish what a telehealth program delivers. With Kova, the evidence question has several layers: which organization provides care, what preparation a pharmacy would dispense, what the subscription purchases and whether published research actually evaluates that offering. Kova’s public documentation describes an online route to compounded semaglutide and tirzepatide, with clinician review, delivery and a companion app. It does not establish that the platform’s outcomes match those of an approved product studied in a clinical trial.
This review examines public pages consulted October 19, 2026, separating documented service terms from clinical evidence. Kova provides unusually specific advertised prices and a useful distinction between initial prescription approval and later billing. Important gaps remain: the exact formulation and dispensing pharmacy for an individual order, numerical service timelines and the complete cancellation and refund provisions. Those gaps do not prove that care is unavailable or inadequate; they identify what a prospective patient still needs to verify before enrolling.
At a glance
- Platform versus medical care
- LifeTech Apps Inc operates Kova’s technology platform and says independent medical groups—not the company—provide clinical services.Sources: [7]
- Advertised medication access
- Kova advertises compounded semaglutide and tirzepatide subject to clinical evaluation, prescribing approval, state availability and pharmacy availability.Sources: [6]
- One-month pricing
- Semaglutide is advertised at $249 for the first month, then $299/month. Tirzepatide is $299 for the first month, then renews at $399; that line does not repeat the renewal period.Sources: [6]
- Different billing rules after enrollment
- The initial charge awaits clinical eligibility and a first prescription, but subsequent recurring charges may precede later reviews, refill requests or prescription renewals.Sources: [7]
Start with the product, not the ingredient name
Kova advertises access to compounded semaglutide and tirzepatide when a licensed clinician prescribes them. Its intake asks about a preference for injectable or oral treatment, but that question does not confirm which medication is available in which route, concentration or presentation. The consulted documentation also does not establish the quantity supplied with each shipment. A named ingredient and a plan duration therefore leave important product-level questions unanswered.
Kova’s terms explicitly acknowledge that compounded medications are not FDA approved and are not FDA-approved generics. FDA recommends using compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. This is not a categorical finding about Kova’s legality or quality. It is a reason to ask the prescribing clinician why a particular preparation is appropriate and exactly what the pharmacy will dispense.
Published medication research does not automatically validate a platform selling access to a compounded preparation. STEP 1 and SURMOUNT-1 did not test Kova’s program, and their results cannot establish outcomes for its compounded products, other routes or individual patients. Our guide to approved medicines and compounded preparations explains that distinction. The same discipline applies to Kova’s commercial claims about results, muscle protection or facial appearance: advertising is not a provider-specific clinical evaluation.
Who operates Kova—and who makes medical decisions?
The terms identify LifeTech Apps Inc as the operator of Kova’s application, website, accounts, portals and enrollment processes. The site lists registration number 10554303 and a registered office in Wilmington, Delaware. More consequentially, the company says it does not provide medical, pharmacy or laboratory services. Clinical services belong to independent medical provider groups and their licensed professionals. Kova is therefore best understood as a technology and access platform, not as the entity performing every part of treatment.
Kova says it works with Telegra’s provider network and identifies Laurie Mercier, MD, alongside Kimberli Hastings, NP, Theresa Vergara, NP, and Craig Sorkin, NP. These are provider-published identities and credentials, not independently verified licenses. The distinction between physician and nurse practitioner also matters: the presence of an MD on a team does not mean every consultation is with a physician. The relevant question is who will actually evaluate the patient and hold responsibility for prescribing.
The site also attributes a nationwide network of 503a and 503b compounding pharmacies to Telegra MD LLC. That description does not independently verify each pharmacy’s classification or identify the pharmacy assigned to a particular order. As our guide to what public provider documents can prove explains, a published network description establishes what the company represents, not an audit of every participant. Patients should obtain the specific clinical group and dispensing pharmacy names for their own care.
What enrollment and nationwide access actually mean
The documented enrollment process begins with a questionnaire about goals, medical history and treatment preferences. A licensed clinician reviews the intake and decides whether GLP-1 medication is appropriate. Kova says no medication ships without provider approval. This establishes a clinical decision point, not guaranteed prescribing. The consulted pages do not provide specific BMI criteria, comorbidity requirements or medical exclusions, so general prescribing thresholds should not be presented as Kova’s own eligibility rules.
Platform users must be at least 18, legally able to enter a binding contract and located in the United States. For clinical services, the patient must be physically in a state or territory where the applicable professional is authorized to practice. Kova advertises care and support in all 50 states, but qualifies specific service availability by licensure and state regulations. Medication availability is separately contingent on state, pharmacy availability and clinician judgment.
People already using a GLP-1 must still complete the medical intake. Kova says a clinician reviews current treatment and medical history before deciding whether care can continue or transition; existing use does not establish automatic acceptance. The public materials do not give numerical review turnaround times or confirm Spanish-language clinical care or interpretation. Someone comparing services can usefully ask about the consultation format, expected review time and language access before assuming that an online intake resolves those practical needs.
The advertised prices are specific; the product details are less so
Kova publishes separate semaglutide and tirzepatide prices for one-, three-, six- and 12-month plans. The longer-plan wording offers a monthly amount or an upfront amount; it should not be rewritten as mandatory prepayment. These prices concern the advertised compounded-medication program, but the consulted price descriptions do not establish an exact route, concentration or presentation. Nor does the plan’s duration prove how much medication arrives at once or establish a minimum commitment.
The subscription is advertised as covering clinician consultations, prescription fulfillment, medication delivery, ongoing support and full companion-app access, with no separate medication charge. A second description qualifies ongoing check-ins as available “where applicable.” Laboratory testing is excluded: a clinician can order and review tests if needed, but the patient pays separately. Kova says insurance is not required and pricing is the same regardless of insurance status. It advises checking potential FSA or HSA reimbursement with the account’s plan provider rather than promising eligibility.
The table preserves the published payment alternatives without calculating savings or annual totals. For the one-month tirzepatide plan, the renewal line states $399 but does not repeat its time unit; that omission should be resolved in the actual purchase terms. More broadly, a lower advertised monthly figure is not evidence of better clinical outcomes. The meaningful comparison includes the exact preparation, expected follow-up, separate laboratory costs and the obligations attached to the selected plan.
| Plan duration | Semaglutide | Tirzepatide |
|---|---|---|
| 1 month | $249 first month; then $299/month | $299 first month; then $399, with renewal period not repeated in that line |
| 3 months | $179/month, or $537 upfront | $249/month, or $747 upfront |
| 6 months | $149/month, or $894 upfront | $229/month, or $1,374 upfront |
| 12 months | $129/month, or $1,548 upfront | $199/month, or $2,388 upfront |
Initial approval and recurring billing are different events
For initial enrollment, Kova’s terms permit a temporary payment authorization hold but say the initial plan charge will not be captured until a clinician determines eligibility and issues the first prescription. If no initial prescription is issued, the hold is released or voided. This is a specific protection around the first charge. It should not be expanded into a promise that every future payment waits for a completed clinical review or a newly issued prescription.
After enrollment, recurring plan charges may be processed on the scheduled billing date before subsequent clinical review, refill requests, prescription renewal or dose changes are completed. The terms expressly separate billing cycles from clinical reviews, prescriptions, refills and shipments. A payment therefore is not, by itself, evidence that a follow-up evaluation happened or that medication is already in transit. Readers should establish how their billing date relates to refill requests and clinical reassessment rather than treating those processes as synchronized.
The terms also say the plan conditions presented at checkout and confirmed in the order control over inconsistent economic terms in the general financial section, except where prohibited by law. Those checkout terms and order confirmations were not reviewed. This makes saving the actual purchase documents especially useful: they should resolve the chosen payment schedule and any plan-specific obligations. The public price grid alone cannot supply those details, and an advertised plan duration should not substitute for the actual agreement.
Follow-up tools are documented, but continuous monitoring is not
Kova describes a provider portal for secure messages, refill requests, delivery tracking and billing management. The companion app is included with every plan at no additional cost and advertises reminders, injection-site records, symptom tracking, protein tracking, treatment history and educational material. Its functions may change. These are concrete organizational tools, but their presence does not establish how often a clinician reviews entries, which observations trigger outreach or whether app use improves clinical outcomes.
The site advertises 24/7 patient support from the medical provider, without specifying a guaranteed response time. The terms make an important limitation explicit: the company does not continuously monitor health, symptoms, medication use or platform activity, and messages or check-ins do not create an emergency service. Our guide to clinical follow-up versus renewal notices addresses this distinction. A useful enrollment question is what scheduled review occurs beyond patient-initiated messages and billing-related contact.
Contact responsibilities are divided. Kova directs general companion-app inquiries to support@trykova.com, while medication, prescription, refill and medical-care questions belong in the patient portal. That separation can help avoid routing a clinical concern to technical support. NIDDK describes follow-up as involving tolerance and response, not simply continuing payment. Kova’s public materials establish access channels, but not a fixed clinical review cadence, a numerical response standard or evidence that every symptom entry receives professional review.
Pharmacy, delivery and product-condition responsibilities
Kova publishes a pharmacy-provider list naming E-RxHub, Absolute Pharmacy, Southend Pharmacy, Strive Pharmacy and Pharmacy Boudreaux’s. Listed contact examples include E-RxHub at (800) 311-5805 and support@e-rxhub.com, and Southend at (855) 414-5356 and info@southendpharmacystore.com. This supplies potential contact paths, but not proof that any named pharmacy would dispense a particular patient’s prescription. Confirming the assigned pharmacy is more useful than assuming that every listed participant handles every product.
Shipping and delivery dates are estimates affected by clinical review, pharmacy processing, product availability and carrier operations. The terms assign patients responsibility for an accurate address, updates before shipment, prompt retrieval and storage according to pharmacy instructions. Subject to applicable law, carrier-confirmed delivery to that address counts as delivery. These provisions do not establish numerical preparation or arrival timelines. A shipment notice, a delivery scan and an acceptable product on arrival are distinct pieces of information.
For an approved shipping claim, Kova may arrange a replacement at no extra charge or, if replacement is not reasonably available, an applicable credit or refund under the governing terms. Dispensed products are not returnable unless the pharmacy directs otherwise. Separately, FDA advises not using an injectable GLP-1 that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Our guide to reading delivery and cold-chain claims explains why arrival alone does not resolve product-condition concerns.
Cancellation and privacy leave document-level questions
Kova’s public page says cancellation is available at any time through the account page or support. Its more specific explanation says access to the active medication plan, upcoming refills, platform clinical care and app ends after the paid period. Restarting may require a new clinical evaluation. Another answer describes access ending upon cancellation without the same timing detail. The paid-period explanation is more precise, but the complete contract is needed to resolve all plan-specific implications.
The reviewed terms excerpt stops before the complete cancellation and refund provisions can be examined. Consequently, this review cannot establish the full refund policy, cancellation notice requirements or possible obligations associated with multi-month plans. Cancellation does not itself mean a refund, and the shipping-claim provision is not a general refund guarantee. Before purchasing, request the complete policy applicable to the chosen plan, including what happens when clinical circumstances or medication availability change after a recurring charge.
The document available at the medical-consent address was titled Consumer Health Data Privacy Notice; it should not be treated as proof of informed telehealth consent. That notice permits operational sharing of consumer health data with AM APPS LTD, an affiliate outside the United States, subject to stated contractual and legal obligations. This does not establish improper handling, but it is a material disclosure. Patients should distinguish privacy permissions from the clinical consent and provider-specific terms that govern their care.
Questions & answers
Does Kova guarantee a prescription after I pay?
No. A clinician must determine eligibility and issue the first prescription before Kova captures the initial plan charge, although a temporary authorization hold may occur. If no first prescription is issued, the hold is released or voided. Later recurring charges follow different rules and may precede subsequent clinical review or prescription renewal.
Can I choose oral semaglutide or injectable tirzepatide?
The intake asks about oral versus injectable preferences, but the consulted documentation does not confirm the medication, formulation, concentration or presentation available for each route. Ask the clinician and assigned pharmacy what would actually be prescribed and dispensed. A preference question is not a product-availability commitment, and neither ingredient name alone establishes that research on another formulation applies.
Are medication and laboratory tests included in Kova’s price?
Kova says the subscription includes medication without a separate medication charge, consultations, prescription fulfillment, delivery, support and the app. Laboratory work is specifically excluded and costs extra if required. The general plan description qualifies ongoing check-ins as applicable to the case, so clarify the expected follow-up rather than assuming a fixed appointment schedule is included.
Does a 12-month plan mean I receive a year of medication at once?
The public documentation does not establish that. Plan duration, billing frequency and shipment quantity are separate questions, and the terms expressly separate billing from prescriptions, refills and shipments. The advertised 12-month plans offer monthly or upfront payment alternatives. Confirm dispensing quantities, refill procedures and any ongoing obligations in the checkout terms before choosing either payment option.
Who should I contact about a refill or medication concern?
Kova directs medication, prescription, refill and clinical questions to the patient portal. Its support@trykova.com address is for general companion-app inquiries. The medical provider advertises 24/7 support, but no guaranteed response interval is documented. The terms explicitly say the platform is not an emergency or continuously monitored service, so messaging availability should not be interpreted as immediate clinical observation.
Will canceling Kova produce a refund?
The consulted documents do not establish a general right to a refund. Kova describes account-page or support cancellation and says access ends after the paid period, but the complete cancellation and refund terms were unavailable in the reviewed excerpt. Ask for the full policy for your selected plan, including notice deadlines and treatment of unused periods; do not infer repayment from permission to cancel.
Our assessment
Kova documents a recognizable service structure: independent clinical evaluation, access to compounded semaglutide or tirzepatide, pharmacy coordination, bundled delivery and digital support. Its published prices and distinction between initial approval and recurring billing help readers understand what is being offered. They do not establish clinical effectiveness, a particular patient’s eligibility or equivalence to studied approved products. The most consequential unresolved issues are the exact dispensed preparation, assigned pharmacy, follow-up cadence and complete plan-specific cancellation and refund terms. For an evidence-focused comparison, Kova merits evaluation as a documented access platform—not as a clinically validated program. Obtain those missing details and the actual checkout agreement before treating the advertised bundle as a fully specified course of care.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Kova — telehealth medical consent ↗
- Kova — official website ↗
- Kova — terms ↗